Nozomi Watanabe

Nozomi Watanabe

Auto-generated profile, based on publicly available information

Nozomi Watanabe

Department of Cardiovascular Physiology, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2019 in Heart
Verified
Journal Article
Closed access
PDF file
NWNozomi Watanabe
Nozomi Watanabe
The diagnosis of acute mitral regurgitation (MR) is often missed or delayed because the clinical presentation is substantially different from that in patients with chronic MR. Management of acute MR depends on the specific aetiology of valve dysfunction and there is a lack of consensus on the optimal therapeutic approach in many patients. In particular, management of secondary MR due to acute ischaemia is challenging because of unique mechanisms of valve incompetence compared with chronic ischaemic MR. Another clinical challenge is management of acute MR due to transient systolic anterior motion of the mitral valve in the acute phase of Takotsubo cardiomyopathy, which commonly resolves within a few weeks. Additionally, iatrogenic MR induced by intraventricular devices is a recently recognised aetiology of acute MR. Acute primary MR typically requires early surgical intervention, for example, with a flail leaflet or endocarditis, because of acute cardiovascular decompensation with an abrupt increase in left atrial pressure. In an emergency situation and high surgical risk, a percutaneous mitral valve edge-to-edge repair is an alternative therapeutic option. Firm diagnosis of the severity and aetiology of acute MR is necessary for proper decision making, including timing and types of surgical intervention.

1 August 2016 in Circulation: Cardiovascular Imaging
Verified
Journal Article
Closed access
PDF file
SNShun Nishino
Shun Nishino
NWNozomi Watanabe
Nozomi Watanabe
TKToshiyuki Kimura
Toshiyuki Kimura
MEMaurice Enriquez-Sarano
Maurice Enriquez-Sarano
TNTatsuya Nakama
Tatsuya Nakama
YSYoshisato Shibata
Yoshisato Shibata
Background—: Previously published evidence on ischemic mitral regurgitation (IMR) and its adverse prognosis after myocardial infarction has been based on the severity of IMR in the subacute or chronic period of myocardial infarction. However, the state of IMR can vary from the early stage to the chronic stage as a result of various responses of myocardium after primary percutaneous coronary intervention (PCI). Methods and Results—: Standard echocardiography was serially performed in 546 consecutive patients with first-onset acute myocardial infarction (1) immediately after their arrival (pre-PCI), (2) before discharge (early post-PCI), and (3) 6 to 8 months after PCI (late post-PCI). The course of IMR after primary PCI and the prognostic impact of the IMR in each phase were investigated. IMR was found in 193/546 (35%) patients at the emergency room. In the acute phase after PCI, IMR improved in 63 patients. IMR worsened in 78 patients despite successful PCI. Shorter onset-to-reperfusion time and nontotal occlusion before PCI were the independent predictors of early improvement of IMR. In the chronic phase, IMR improved in 79 patients and worsened in 36 patients. Lower peak creatine kinase–myocardial band was an independent predictor of late improvement of IMR. IMR before PCI worsened 30-day prognosis ( P =0.02), and persistent IMR in the chronic phase worsened long-term prognosis ( P =0.04) after primary PCI. Conclusions—: Degrees of IMR changed in the early and chronic phase after primary PCI for acute myocardial infarction. IMR on arrival and persistent IMR in the chronic phase worsened short-term and long-term prognosis after acute myocardial infarction, respectively.

1 April 2018 in Circulation: Cardiovascular Imaging
Verified
Journal Article
Closed access
PDF file
SNShun Nishino
Shun Nishino
NWNozomi Watanabe
Nozomi Watanabe
TKToshiyuki Kimura
Toshiyuki Kimura
NKNehiro Kuriyama
Nehiro Kuriyama
YSYoshisato Shibata
Yoshisato Shibata
Background: Little is known on the mechanism of acute ischemic mitral regurgitation (IMR) caused by sudden-onset left ventricular dysfunction in acute myocardial infarction (MI). We sought to investigate the mitral valve (MV) complex geometry in acute IMR in comparison with chronic IMR by 2-dimensional and 3-dimensional transthoracic echocardiography. Methods and Results: Forty-four first-onset acute MI and 36 previous MI with ≥moderate IMR were examined by 2-dimensional/3-dimensional transthoracic echocardiography. MV morphology was quantitatively analyzed and compared between the 2 groups. Left ventricular end-diastolic volume and left ventricular end-systolic volume were significantly smaller in acute IMR than in chronic IMR (40.8 [33.1–48.3] versus 88.8 [66.5–108.8] mL/m 2 ; P <0.001, 17.8 [17.0–30.1] versus 49.5 [34.2–73.7] mL/m 2 ; P <0.001). MV tenting volume and annular area were significantly smaller in acute IMR compared with chronic IMR (0.98 [0.66–1.68] versus 1.88 [1.16–2.65] cm 3 /m 2 ; P =0.008, 5.17 [4.80–5.86] versus 5.81 [5.47–8.22] cm 2 /m 2 ; P =0.008). Leaflet surface area was significantly smaller in acute IMR than in chronic IMR (5.78 [5.16–6.32] versus 7.56 [6.89–11.32] cm 2 /m 2 ; P <0.001). The ratio of MV leaflet surface area and MV annular area was significantly smaller in acute IMR than in chronic IMR (1.08 [1.01–1.14] versus 1.28 [1.24–1.37]; P =0.001). Conclusions: Sudden-onset left ventricular dysfunction in acute MI may cause loss of coaptation of the MV even with a relatively mild degree of valve tethering. Compared with previously studied chronic IMR, a smaller leaflet area without leaflet adaptation and a larger hemodynamic burden at the acute onset of MI could result in clinically significant IMR despite relatively small leaflet tethering.

26 October 2021 in Bioengineering
Verified
Journal Article
Open access
PDF file
Harishkumar MadhyasthaHarishkumar Madhyastha
Harishkumar Madhyastha
MRMadhyastha Radha
Madhyastha Radha
NYNakajima Yuichi
Nakajima Yuichi
GMGothandam Kodiveri Muthukalianan
Gothandam Kodiveri Muthukalianan
KOKaoru Oe
Kaoru Oe
WNWatanabe Nozomi
Watanabe Nozomi
Exosomes are the master transporters of genes, RNAs, microRNAs, proteins, and lipids. They have applications in major diseases, including cancer, cardiovascular diseases, neurological disorders, and diabetes mellitus. Delivery of the exosomes to recipient cells is governed by the functional heterogenicity of the tissues. Engineered exosomes are promising tools in tissue regeneration. In addition to their role as intracellular communication cargos, exosomes are increasingly primed as standard biomarkers in the progression of diseases, thereby solving the diagnostic dilemma. Futuristic empowerment of exosomes with OMICS strategy can undoubtedly be a bio-tool in translational medicine. This review discusses the advent transformation of exosomes in regenerative medicine and limitations that are caveats to broader applications in clinical use.

20 March 2020 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
YGYuhei Goriki
Yuhei Goriki
ATAtsushi Tanaka
Atsushi Tanaka
KNKensaku Nishihira
Kensaku Nishihira
AKAtsushi Kawaguchi
Atsushi Kawaguchi
MNMasahiro Natsuaki
Masahiro Natsuaki
KNKoichi Node
Koichi Node
In emergency clinical settings, it may be beneficial to use rapidly measured objective variables for the risk assessment for patient outcome. This study sought to develop an easy-to-measure and objective risk-score prediction model for in-hospital mortality in patients with ST-segment elevation myocardial infarction (STEMI). A total of 1027 consecutive STEMI patients were recruited and divided into derivation (n = 669) and validation (n = 358) cohorts. A risk-score model was created based on the combination of blood test parameters obtained immediately after admission. In the derivation cohort, multivariate analysis showed that the following 5 variables were significantly associated with in-hospital death: estimated glomerular filtration rate <45 mL/min/1.73 m2, platelet count 1.6 ng/mL, and blood sugar ≥200 mg/dL. The risk score was weighted for those variables according to their odds ratios. An incremental change in the scores was significantly associated with elevated in-hospital mortality (p < 0.001). Receiver operating characteristic curve analysis showed adequate discrimination between patients with and without in-hospital death (derivation cohort: area under the curve (AUC) 0.853; validation cohort: AUC 0.879), and there was no significant difference in the AUC values between the laboratory-based and Global Registry of Acute Coronary Events (GRACE) score (p = 0.721). Thus, our laboratory-based model might be helpful in objectively and accurately predicting in-hospital mortality in STEMI patients.

1 November 2017 in Progress in Cardiovascular Diseases
Verified
Journal Article
Closed access
NWNozomi Watanabe
Nozomi Watanabe
SMSimon Maltais
Simon Maltais
SNShun Nishino
Shun Nishino
TOTara A. O'DOnoghue
Tara A. O'DOnoghue
JHJudy Hung
Judy Hung